Synthesis and evaluation of 99mTc/99Tc-MAG3-biotin conjugates for antibody pretargeting strategies

Nuclear Medicine and Biology

Volumn 25, Issue 7, 1998, Pages 611-619

  Van Gog, Frank B ^a   Visser, Gerard W M ^b   Gowrising, Radjish W A ^a   Snow, Gordon B ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

99mTc labeled biotin; Antibody pretargeting; Biodistribution in nude mice; Plasma stability; Radioimmunoscintigraphy; Radioimmunotherapy

Indexed keywords

BIOCYTIN; BIOTIN; BIOTIN DERIVATIVE; MERTIATIDE TC 99M; TECHNETIUM 99M; DRUG DERIVATIVE; TRACER;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG DISTRIBUTION; IMMUNOSCINTIGRAPHY; MOUSE; NONHUMAN; PLASMA CLEARANCE; RADIOIMMUNOTHERAPY; URINARY EXCRETION; ANIMAL; CHEMISTRY; DRUG STABILITY; FEMALE; METHODOLOGY; NUDE MOUSE; RADIOIMMUNOASSAY; TISSUE DISTRIBUTION;

ANIMALS; BIOTIN; DRUG STABILITY; FEMALE; MICE; MICE, NUDE; RADIOACTIVE TRACERS; RADIOIMMUNODETECTION; TECHNETIUM TC 99M MERTIATIDE; TISSUE DISTRIBUTION;

EID: 0031593888     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00022-5     Document Type: Article

References (17)

1. 111In-DTPA-biocytin. Nucl. Med. Biol. 23:1992;459-466.
2. Axworthy D.B., Sanderson J.A., Gustavson L.M., Su F.M., Srinivasan A., Reno J.M., et al. Antibody pretargeting for radioimmunotherapy A three-step approach in tumored nude mice . J. Nucl. Med. 33:1992;880.
3. Chauhan J., Dakshinamurti K. Purification and characterization of human serum biotinidase. J. Biol. Chem. 261:1986;4268-4275.
4. Coursey B.M., Cessna J., Garcia-Torano E. The standardization and decay scheme of rhenium-186. Int. J. Radiat. Appl. Instrum. Part A. 42:1991;865-869.
5. 186Re-labeled monoclonal antibody E48. Cell. Biophysics. 24:1994;135-142.
6. Goodwin D.A. Tumor pretargeting Almost the bottom line . J. Nucl. Med. 36:1995;876-879.
7. 14C]-biotin for kinetic studies and for assay . Biochem. J. 89:1963;585-591.
8. Hnatowich D.J., Virzi F., Rusckowski M. Investigations of avidin and biotin for imaging applications. J. Nucl. Med. 28:1987;1294-1302.
9. Jeong J.M., Kinuya S., Paik C.H., Saga T., Sood V.K., Neumann R.D., et al. Synthesis of a Tc-99m MAG3-biotin conjugate as a biliary agent. J. Label. Compd. Radiopharm. 32:1992;88-90.
10. Kalofonos H.P., Rusckowski M., Siebecker D.A., Sivolapenko G.B., Snook D., Lavender J.P., et al. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies Preliminary communication . J. Nucl. Med. 31:1990;1791-1796.
11. 99mTc]PnAO-biotin . Eur. J. Nucl. Med. 21:1994;314-321.
12. Rosebrough S.F. Plasma stability and pharmacokinetics of radiolabeled deferoxamine-biotin derivatives. J. Pharmacol. Exp. Ther. 265:1993;408-415.
13. Stoldt H.S., Aftab F., Chinol M., Paganelli G., Luca F., Testori A., et al. Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Eur. J. Cancer. 33:1997;186-192.
14. Su F.M., Gustavson L.M., Axworthy D.B., Lyen L.J., Theodore L.J., Fritzberg A.R., et al. Characterization of a new Y-90-labeled DOTA-biotin for pretargeting. J. Nucl. Med. 36:1995;154P.
15. van Gog F.B., Visser G.W.M., Klok R., van der Schors R., Snow G.B., van Dongen G.A.M.S. Monoclonal antibodies labelled with rhenium-186 using the MAG3 chelate Relation between the number of chelated groups and biodistribution characteristics . J. Nucl. Med. 37:1996;352-362.
16. 186Re-labeling of monoclonal antibodies for clinical application Pitfalls and solutions . Cancer. 80:1997;2360-2370.
17. 186Re using the MAG3 chelate for radioimmunotherapy of cancer A technical protocol . J. Nucl. Med. 34:1993;1953-1963.